NANOBIOTIX announced that partner LianBio has entered into an agreement with Janssen Pharmaceutica NV, a Johnson & Johnson company, whereby LianBio has assigned to Janssen LianBio’s exclusive rights to develop and commercialize potential first-in-class radioenhancer NBTXR3 in China, South Korea, Singapore, and Thailand.
¿Quieres utilizar el poder de ChatGPT sin problemas? ¡No es necesario registrarse ni proporcionar información personal! Descubre cinco formas increíbles de aprovechar ChatGPT al máximo en este artículo. Imagínate con la increíble capaci …
AstraZeneca has entered into a definitive agreement to acquire Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune diseases, furthering the AstraZeneca cell therapy ambition.
Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies for the treatment of cancer and autoimmune diseases, announced it has entered into a definitive agreement to be acquired by AstraZeneca.
LegoChem Biosciences, Inc. announced on December 22 that it has entered into a license agreement with Janssen Biotech, Inc., a Johnson & Johnson company, to develop and commercialize LCB84, a Trop2 directed antibody drug conjugate.
LegoChem Biosciences Announces License Agreement for LCB84 Trop2-Targeted ADC Read More »
PharmaBlock Sciences, Inc. has announced the successful attainment of Energy Management System Certification for its headquarters and R&D center in Nanjing, as well as its manufacturing facilities in Zhejiang and Shandong, China.
PharmaBlock Obtained ISO 50001 Certification, Advancing Sustainable Development Read More »
Syncell, a life science technology company known for pioneering next-generation spatial proteomics, is pleased to announce the inauguration of its US main office in Watertown, Massachusetts.
Syncell Expands Into the United States With a New Office in Watertown, MA Read More »
Asieris Pharmaceuticals announced that its product, APL-2301, used for the treatment of Acinetobacter baumannii infections, was approved for Phase I clinical trials in Australia.
Changchun GeneScience Pharmaceutical, a subsidiary of Changchun High-Tech Industries, held a groundbreaking ceremony for its new global headquarters and research & development center at Shanghai Zhangjiang International Medical Park on December 15th.
GenSci Launches Global Innovation Hub in Shanghai Read More »
Zealand Pharma A/S, a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that the U.S. Food and Drug Administration has issued a Complete Response Letter for Part 1 of the New Drug Application for dasiglucagon for the prevention and treatment of hypoglycemia in pediatric patients 7 days of age and
